These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 4957708)

  • 21. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
    Cohen CJ; Bruckner HW; Goldberg JD; Holland JF
    Clin Obstet Gynaecol; 1983 Aug; 10(2):307-24. PubMed ID: 6413114
    [No Abstract]   [Full Text] [Related]  

  • 23. Cytotoxic agents in the treatment of malignant disease.
    Br Med J; 1968 Nov; 4(5628):438-9. PubMed ID: 4972069
    [No Abstract]   [Full Text] [Related]  

  • 24. [The chemotherapy of ovarian carcinomas].
    Novikova L; Blohkin N
    Gynecol Prat; 1967; 18(6):537-44. PubMed ID: 4987388
    [No Abstract]   [Full Text] [Related]  

  • 25. [Chemotherapy in ovarian cancer].
    Nyström C
    Nord Med; 1970 Dec; 84(50):1601. PubMed ID: 4997057
    [No Abstract]   [Full Text] [Related]  

  • 26. [Determination of individual sensitivity of ovarian tumors to alkylating agents].
    Vinnitskaia VK; Kulik GI; Abragam KA; Oderiĭ-Korol' VI
    Vopr Onkol; 1971; 17(7):27-31. PubMed ID: 5002943
    [No Abstract]   [Full Text] [Related]  

  • 27. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The state of hemopoiesis in the regional perfusion of malignant tumors of the extremities with sarcolysin, thio-TEPA and cyclophosphane].
    Levin AO; Babinina VF
    Vopr Onkol; 1967; 13(2):48-54. PubMed ID: 4971006
    [No Abstract]   [Full Text] [Related]  

  • 29. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
    van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
    Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclophosphamide. Evaluation in recurrent and progressive ovarian cancer.
    Decker DG; Malkasian GD; Mussey E; Johnson CE
    Am J Obstet Gynecol; 1967 Mar; 97(5):656-65. PubMed ID: 4959953
    [No Abstract]   [Full Text] [Related]  

  • 32. Protection of mammalian cells against chemotherapeutic agents thiotepa, 1,3-N,N'-bis(2-chloroethyl)-N-nitrosourea, and mafosfamide using the DNA base excision repair genes Fpg and alpha-hOgg1: implications for protective gene therapy applications.
    Xu Y; Hansen WK; Rosenquist TA; Williams DA; Limp-Foster M; Kelley MR
    J Pharmacol Exp Ther; 2001 Mar; 296(3):825-31. PubMed ID: 11181913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
    Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
    Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative evaluation of combined and complex methods of treatment of malignant tumors of the ovaries].
    Milian OV; Pryluts'ka NH
    Pediatr Akus Ginekol; 1975; (6):51-4. PubMed ID: 812047
    [No Abstract]   [Full Text] [Related]  

  • 35. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Early diagnosis and effective treatment of ovarian cancer].
    Sawada M; Matsui Y; Okudaira Y
    Gan To Kagaku Ryoho; 1983 May; 10(5):1251-8. PubMed ID: 6191676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mobilisation of peripheral blood progenitor cells using chemotherapy, stem cell factor and filgrastim or chemotherapy plus filgrastim alone: a randomised study.
    Weaver A; Woll PJ; Lind M; Jenkins B; Gill C; Dexter TM; Testa NG; Crother D
    Sangre (Barc); 1997 Apr; 42 Suppl 1():34. PubMed ID: 9335192
    [No Abstract]   [Full Text] [Related]  

  • 38. Chemotherapy of ovarian cancer with melphalan.
    Rutledge F
    Clin Obstet Gynecol; 1968 Jun; 11(2):354-66. PubMed ID: 4971815
    [No Abstract]   [Full Text] [Related]  

  • 39. [A patient with ovarian cancer metastasis cured (?) by cytostatic agents and died from acute myeloid leukemia].
    Sypkens Smit CG; Meyler L
    Ned Tijdschr Geneeskd; 1970 Sep; 114(39):1620-3. PubMed ID: 4990178
    [No Abstract]   [Full Text] [Related]  

  • 40. [Cytostatic chemotherapy in the treatment of malignant tumors].
    Langhammer H; Klemm J; Pabst HW
    Arztl Forsch; 1966 Aug; 20(8):393-403. PubMed ID: 6014703
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.